Short and long-term clinical impact of transcatheter aortic valve implantation in Portugal according to different access routes: Data from the Portuguese National Registry of TAVI

Autor: Eduardo Oliveira, João Silveira, João Carlos Silva, Pedro Braga, Duarte Cacela, João Brito, Rui Campante Teles, Cláudio Guerreiro, Pedro Carrilho Ferreira, Manuel de Sousa Almeida, Lino Patrício, Sérgio Madeira, José Baptista, Pedro Canas da Silva, Vasco Gama Ribeiro, Bruno M. Silva
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
medicine.medical_specialty
lcsh:Diseases of the circulatory (Cardiovascular) system
Clinical variables
Transcatheter aortic
Insuficiência cardíaca
Insuficiência Cardíaca
Heart failure
HSM CAR
Cumulative survival
TAVI
Transcatheter Aortic Valve Replacement
03 medical and health sciences
0302 clinical medicine
Severe Aortic Valvular Disease
Substituição da Valva Aórtica Transcateter
medicine
Humans
030212 general & internal medicine
Registries
General Environmental Science
Aged
Aged
80 and over
Access route
Portugal
business.industry
Mean age
Aortic Valve Stenosis
language.human_language
Doença valvular aórtica grave
Surgery
Treatment Outcome
030228 respiratory system
lcsh:RC666-701
language
General Earth and Planetary Sciences
VAP
Female
National registry
Portuguese
Cardiology and Cardiovascular Medicine
business
Lower mortality
Zdroj: Revista Portuguesa de Cardiologia (English Edition), Vol 39, Iss 12, Pp 705-717 (2020)
Revista Portuguesa de Cardiologia, Vol 39, Iss 12, Pp 705-717 (2020)
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
Popis: Introduction: The Portuguese National Registry of Transcatheter Aortic Valve Implantation records prospectively the characteristics and outcomes of transcatheter aortic valve implantation (TAVI) procedures in Portugal. Objectives: To assess the 30-day and one-year outcomes of TAVI procedures in Portugal. Methods: We compared TAVI results according to the principal access used (transfemoral (TF) vs. non-transfemoral (non-TF)). Cumulative survival curves according to access route, other procedural and clinical variables were obtained. The Valve Academic Research Consortium-2 (VARC-2) composite endpoint of early (30-days) safety was assessed. VARC-2 predictors of 30-days and 1-year all-cause mortality were identified. Results: Between January 2007 and December 2018, 2346 consecutive patients underwent TAVI (2242 native, 104 valve-in-valve; mean age 81±7 years, 53.2% female, EuroSCORE-II - EuroS-II, 4.3%). Device success was 90.1% and numerically lower for non-TF (87.0%). Thirty-day all-cause mortality was 4.8%, with the TF route rendering a lower mortality rate (4.3% vs. 10.1%, p=0.001) and higher safety endpoint (86.4% vs. 72.6%, p5% (p5% (p
Databáze: OpenAIRE
Externí odkaz: